Full Papers
Why are Behçet’s disease patients always exhausted?
A.A. Senusi1, J. Liu2, D. Bevec3, L.A. Bergmeier4, M. Stanford5, D. Kidd6, A. Jawad7, S. Higgins8, F. Fortune9
- Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
- Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
- THERAMetrics Discovery AG, Stans, Switzerland.
- Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
- Behçet’s Centre of Excellence, Royal London Hospital, London, UK.
- Behçet’s Centre of Excellence, Royal London Hospital, London, UK.
- Behçet’s Centre of Excellence, Royal London Hospital, London, UK.
- Behçet’s Centre of Excellence, Royal London Hospital, London, UK.
- Centre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK. f.fortune@qmul.ac.uk
CER11013
2018 Vol.36, N°6 ,Suppl.115
PI 0053, PF 0062
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 30299243 [PubMed]
Received: 01/12/2017
Accepted : 28/03/2018
In Press: 05/10/2018
Published: 13/12/2018
Abstract
OBJECTIVES:
Patients with Behçet’s disease (BD) constantly complain of fatigue and many have problems with poor sleep. This ultimately has a major impact on all aspects of normal living. To attempt to understand this, Artificial Intelligence (AI) was used to identify potential biomarkers. These were alpha-melanocyte stimulating hormone (α-MSH), vasoactive intestinal peptide (VIP) and some inflammatory cytokines. We assessed the association of fatigue, quality of sleep and disease activity with circulating concentration of α-MSH, VIP and inflammatory cytokines.
METHODS:
There were 127 participants, 97 BD patients, and 30 healthy controls (HC). All completed the Multi-Dimensional Assessment of Fatigue questionnaire (MAF) and the Pittsburgh Sleep Quality Index (PSQI) on the day of their clinical assessment. Enzyme-linked immunosorbent assays (ELISA) were used to evaluate the serum concentrations of α-MSH, VIP and cytokines (IL-1β, IL-6, IL-10, and TNF-α).
RESULTS:
64% of BD patients experienced high fatigue scores, and 63% had poor quality of sleep. When BD and HC were compared the MAF and PSQI scores as well as the serum concentrations of α-MSH, VIP, and IL-6 were significantly higher in BD (p values were: 0.001, 0.001, 0.001, 0.004 and 0.036, respectively). Both α-MSH and IL-6 had significant impact on MAF and PSQI. Interestingly, VIP had a significant influence on PSQI and disease activity, but not on MAF.
CONCLUSIONS:
A better understanding of these complex clinical and biochemical interactions between α-MSH, VIP and IL-6 might lead to the development of novel approaches to manage fatigue and sleep disorders as well as disease activity in BD patients.
